Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how long-term LEAP-002 data provides critical reassurance around Lenvima’s durability and safety in treating ...

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how consistent survival data from the LEAP-002 study reaffirms lenvatinib’s value in first-line treatment of ...

The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association ...

CHICAGO, Sept 30 (Reuters) - Clear evidence this week that Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab drug lecanemab slows cognitive decline in early stage dementia has ...

Japanese drugmaker Eisai today revealed that it has launched its Urece (dotinurad) in China as a treatment for gout. Urece ...

Eisai is continuing to advance care in Alzheimer’s disease via this multi-dimensional, yet targeted path to our ultimate goal: prevention and stopping progression.

Eisai Pharma is set to establish a new Global Capability Center (GCC) in Visakhapatnam, aiming to boost its digital ...

Japan's Eisai Co Ltd will surrender its rights to share profit from Aduhelm, the Alzheimer's treatment drug jointly developed with U.S. partner Biogen Inc , and instead receive sales royalties ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value for money”.

Eisai officials said the new study recruited 1,795 people with earlier Alzheimer's disease and amyloid beta in the brain. Participants received either a 10 mg per kilogram dose every two weeks ...

Eisai Co. said a volunteer died while using the company’s experimental Alzheimer’s drug lecanemab in a clinical trial, but that it wasn’t clear if the death was directly caused by the drug ...